Special Authority: Empagliflozin and Semaglutide (inj)

  • Version
  • Download 928
  • File Size 361.87 KB
  • File Count 2
  • Create Date January 9, 2023
  • Last Updated April 24, 2024

Special Authority: Empagliflozin and Semaglutide (inj)

Pharmacare now considers SGLT2 and GLP1 (injectable) products as 2nd line diabetes drugs - after Metformin. The attached eFORMS are specific to these products.  Note that approval for a DPP4 product (a separate eFORM needed) cancels approval for either of these and vice versa.

V2_Apr24_2024 has the updated 2023 background.  The previous one is no longer accepted.

There are two versions - one with a wet signature only (Stan Hurwitz), and one with signature stamp (John Yap) as the default and a wet signature as a back-up option.

Attached Files and Latest Versions

FileAction
SA_Empagliflozin_Semaglutide_V2_Apr24_2024.zipDownload
Ozempic-SA.zip - wet signature onlyDownload